SEC
Based on 1 publication(s) in Google Scholar
SEC induces activation of ANXA7 GTPase via the AMPK/mTORC1/STAT3 signaling pathway. SEC selectively promotes apoptosis in cancer cells, expressing a high level of ITGB4 by inducing ITGB4 nuclear translocation.
For research use only. We do not sell to patients.
- Purity: 98.26%
- CAS No.: 1802997-81-4
- Formula: C22H23ClN2O5
- Molecular Weight:430.88
-
Storage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) SEC
More
Biological Activity
SEC (20 μM) inhibits the cell migration of HEK 293T RKIP / cells and PC3 prostate cancer cells[1].
SEC (20 μM) significantly increases AMPK phosphorylation in PC3 cells, which is inverted by ANXA7 GTPase specific inhibitor ABO, indicating that activated ANXA7 with enhanced phosphorylation level promotes AMPK phosphorylation (cell selectively)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK293T RKIP−/− cells.[1]
-
Concentration:20 µM.
-
Incubation Time:24 h.
-
Result:Suppressed HEK293T RKIP−/− cell migration while had no effect on HEK293T RKIP+/+ cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Luciferase-labeled PC-3M-Luc cells (2×106 per 50 µL sterile HBSS−/−) are orthotopically inoculated into the prostates of 8-week-old nude mice[1].
-
Dosage:3 mg/kg/day or 18 mg/kg/day.
-
Administration:IP daily for 3 weeks.
-
Result:Suppressed the lymph node metastatic capacities of PC-3M-Luc cells in the nude mice model.
Decreased the mRNA level of CCL2, APLN and IL6ST in implanted tumors.
Did not affect the body weight of the mice.
Chemical Information
-
CAS No. 1802997-81-4
-
Appearance Oil
-
Molecular Weight 430.88
-
Formula C22H23ClN2O5
-
Color Light yellow to yellow
-
SMILES
O=C(OCC)C1=CC(C2=CC=C(C=C2)OC)=NN1C[C@@H](COC3=CC=C(C=C3)Cl)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
DMSO : 100 mg/mL (232.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.80 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (5.80 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. ShuYan Liu, et al. SEC-induced Activation of ANXA7 GTPase Suppresses Prostate Cancer Metastasis. Cancer Lett. 2018 Mar 1;416:11-23. [Content Brief]
[2]. ShuYan Liu, et al. A small molecule induces integrin β4 nuclear translocation and apoptosis selectively in cancer cells with high expression of integrin β4. Oncotarget. 2016 Mar 29; 7(13): 16282–16296. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3208 mL | 11.6042 mL | 23.2083 mL | 58.0208 mL |
| 5 mM | 0.4642 mL | 2.3208 mL | 4.6417 mL | 11.6042 mL | |
| 10 mM | 0.2321 mL | 1.1604 mL | 2.3208 mL | 5.8021 mL | |
| 15 mM | 0.1547 mL | 0.7736 mL | 1.5472 mL | 3.8681 mL | |
| 20 mM | 0.1160 mL | 0.5802 mL | 1.1604 mL | 2.9010 mL | |
| 25 mM | 0.0928 mL | 0.4642 mL | 0.9283 mL | 2.3208 mL | |
| 30 mM | 0.0774 mL | 0.3868 mL | 0.7736 mL | 1.9340 mL | |
| 40 mM | 0.0580 mL | 0.2901 mL | 0.5802 mL | 1.4505 mL | |
| 50 mM | 0.0464 mL | 0.2321 mL | 0.4642 mL | 1.1604 mL | |
| 60 mM | 0.0387 mL | 0.1934 mL | 0.3868 mL | 0.9670 mL | |
| 80 mM | 0.0290 mL | 0.1451 mL | 0.2901 mL | 0.7253 mL | |
| 100 mM | 0.0232 mL | 0.1160 mL | 0.2321 mL | 0.5802 mL |